IMBiologics has put together a clinical development team with a background covering the full value chain of antibody-drug development. Enriched with practical experiences which allow efficient navigation through CMC as well as IND/NDA requirements, we are prepared to develop innovative antibody drugs with immunomodulatory function targeting novel treatment mechanisms. Further, IMB’s proprietary platform technology powers continuous pipeline expansion, creating the opportunity for collaboration with global partners and the development of novel antibody drugs for the global market.

Two Track Business Strategy (Secure Early Clinical Pipeline & Future Platform Technology)→ Quantum Jump-up to Innovative Drug Development

IMBiologics is open for any partnership to advance medicine for human health